Post by
general360 on Dec 15, 2020 2:38pm
other compounds?
anyone else see this in the md&a? pg 24:
In addition to apabetalone, we have commenced preclinical testing on other BET inhibitors in our library of compounds which demonstrate similar efficacy and potency on important markers of vascular inflammation, acute phase response, complement and coagulation. These compounds will be further analyzed and explored for their potential use in orphan disease indications.
finally hearing about other compounds? is that beyond the 20 other that were discussed at the AGM 2 or maybe 3 long years ago?
is there a renewed focus on orphan diseases?
thought some of the other 20 compounds were for big name diseases, not orphans....
is that what we'll hear about at the AGM? contnued excitement? we've done nothing w/ the 1st 20 or so compounds, now we're on to the next batch?
not much else new in the md&a...pretty bleak!
liking the price action today, head scratcher fer sure, again.....spike up at open, then havent done much since the first 45min of the day!
go rvx go...